Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®

Berkeley Heights, New Jersey, October 30, 2025

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic pharmaceuticals in the United States, announced today the launch of Everolimus Tablets, 1mg, a generic version of Zortress^® by Novartis, under the therapeutic class of immunosuppressant. This product was developed in collaboration with Natco Pharma Limited, India. The product is expected to be available starting October 30, 2025.

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. The product will be available predominantly in retail, mail order pharmacies, as well as clinics.

“We are excited to now offer all strengths of Everolimus Tablets in both bottles and blister card configurations. Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023. We continue to focus on the development of therapies that provide affordable access to all patients and address unmet medical needs,” states Brian Guy, President and CCO of Breckenridge Pharmaceutical, Inc.

*Please visit www.breckenridgepharma.com for the full prescribing information including warnings, precautions, and adverse reactions.

**All brand names and trademarks are the property of their respective owners.